Canada’s diabetes patients pay a fraction of what the NHS does for Ozempic. The reason is simple: Canada uses a national drug agency to negotiate hard. Britain, meanwhile, lets market forces dictate prices.
The result? A system that rewards shareholders over patients. Now, with US tariffs threatening drug supply chains, the NHS is finally demanding reform.
But will the Treasury listen? The bottom line is clear: we are paying for political cowardice.
